FDA Approves Pembrolizumab + Axitinib for Advanced Renal Cell Carcinoma
On April 19, the FDA approved pembrolizumab (Keytruda, Merck & Co. Inc.) plus axitinib (Inlyta, Pfizer Inc.) for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
In Person Conference & ConventionJuly 18, 2026 at 3:30 PM CDT5005 Glumack Drive, Minneapolis, MN, USAInterContinental Hotel Minneapolis – St. Paul Airport, Minneapolis
In Person Conference & ConventionAugust 12, 2026 at 5:30 PM HST6600 Kalanianaʻole Highway suite 110, Honolulu, HI 96825, USARoy's Restaurants – Hawaii Kai, Honolulu
LOS 2026 Cancer Congress - National Oncology Updates
In Person Conference & ConventionAugust 14, 2026 at 11:00 AM CDT859 Convention Center Blvd, New Orleans, LA, USANew Orleans Marriott Warehouse Art District, New Orleans
